Systemic Lupus Erythematous and Malignancy Risk: A Meta-Analysis

Lihong Cao(Hangzhou First People's Hospital), Jie Jin(Beijing Institute of Technology), Gaixiang Xu(Hangzhou First People's Hospital), Ping Liu(Nanfang Hospital), Jinghan Wang(Anhui University), Xiaoying Zhao(Handan College), Yongmin Tang(Children's Hospital of Zhejiang University), Haitao Meng(First Affiliated Hospital Zhejiang University), Hongyan Tong(First Affiliated Hospital Zhejiang University)
PLoS ONE
April 17, 2015
10.1371/journal.pone.0122964
Cited by 115

Related Papers

MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|396
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2013|247
Ki-67 is a valuable prognostic predictor of lymphoma but its utility varies in lymphoma subtypes: evidence from a systematic meta-analysis
|BMC Cancer|2014|146
Induction of USP25 by viral infection promotes innate antiviral responses by mediating the stabilization of TRAF3 and TRAF6
|Proceedings of the National Academy of Sciences|2015|132